| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Claude Nicaise is Director at SRPT. Claude Nicaise's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $897K at current prices.
The SRPT filings lean toward selling, a net 2,491 shares.
Claude Nicaise has 25 Form 4 filings on record from June 2015 to July 2026, across 4 companies: Director at Gain Therapeutics (GANX), 2022–2026; Director at Sarepta Therapeutics (SRPT), 2015–2026; Director at Cassava Sciences (SAVA), 2023–2025, and 1 more.
The 40 reported transactions were 25 option or other derivative awards, 11 stock awards, 2 option exercises and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $248K.
The only open-market sale was 2,491 shares of SRPT at an average $99.64 on March 12, 2025, about $248K. Twelve months later SRPT was down 83%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2025 | SRPT Sarepta Therapeutics, Inc. | Director | Sale+OE | 2,491 | $99.64 | $248,203.24 | -8.2% | -60.8% | -82.9% |